Podcast appearances and mentions of guillermo garcia

VOV1 - Với những thiết kế sang trọng và tinh tế, sản phẩm của Guillermo Garcia không chỉ gây ấn tượng trong giới thời trang mà còn truyền tải thông điệp về bảo vệ môi trường, thúc đẩy xu hướng tiêu dùng có trách nhiệm với hành tinh xanh.

En el programa d'avui tenim 3x1 en política, rebem la visita dels consellers del PSC de Tarragona, Nacho Garcia, Guillermo Garcia de Castro i Mario Soler, els més joves del consistori tarragoní, per posar-los a prova amb diferents reptes. Ah, i feliç dia de la ràdio, llarga vida a aquest mitjà! podcast recorded with enacast.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

Nosotros somos “Abriendo Sports” un show deportivo que les brinda entretenimiento de una forma especial, con entrevistas a atletas del maravilloso mundo del deporte. Nos puedes encontrar de lunes a viernes por KQ 94.5 FM de 7 a 9 AM, para cuando ya no tengas mas episodios que escuchar aquí. Acompáñanos! Conducción: Vian Araujo y Ricardo Rodríguez Producción: Juanfrank Kranwinkel, Juan Báez y La Cabina Studios

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/SZU865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/SZU865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/SZU865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/SZU865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/SZU865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/SZU865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb and Geron.Disclosure information is available at the beginning of the video presentation.

In this episode, Kemin production team members Guillermo Garcia and Jeff Grenier talk about Kemin's plans for a $28M expansion at its global headquarters, how they are recruiting globally to meet demands in their Des Moines headquarters and globally to become Kemin's largest pet food manufacturing plant in South America and its acquisition of GLF Ingredienti Alimentari to strengthen its position in the EMEA meat industry. As they open their new manufacturing facility in Verona, Missouri, to produce its Proteus® line of clean-label functional proteins, they become the first facility to do so. Jeff and Guillermo talk about global recruiting, production, and dig deep on how this new warehouse facility will bring a whole new level of efficiency and coordination for the global giant.  With its roots in Des Moines, Kemin's story is a treasure trove of best practices in culture, automation, biotechnology and agriscience.  Take a listen!  You'll be glad you did.  For more information on this amazing company, go to: https://www.kemin.com/na/en-us/company/curiosity. They epitomize innovation and create a valuable manufacturing titan to showcase all things possible.   Thanks to the Iowa Economic Development Authority and Toggle for their generous sponsorship.  Hear the full show:  https://iowapodcast.com/kemin-manufacturing               

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting; Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS; Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes; and Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting; Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS; Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes; and Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting; Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS; Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes; and Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting; Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS; Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes; and Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting; Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS; Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes; and Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting; Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS; Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes; and Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Dr. Guillermo Garcia Manero explains the new authorization for use of the drug, Reblozyl®.

In today's episode Guillermo Garcia, co-founder and CEO of Smarthop joins us to talk about the ways TMS systems and tech platforms can help smaller fleets level the playing field when competing for freight.  Follow the Loaded and Rolling Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode Guillermo Garcia, co-founder and CEO of Smarthop joins us to talk about the ways TMS systems and tech platforms can help smaller fleets level the playing field when competing for freight.  Follow the Loaded and Rolling Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

FreightWaves' Mike Baudendistel discusses last week's retail earnings and interviews Guillermo Garcia, Co-Founder and CEO of SmartHop, a fleet management software company. Follow The Stockout Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

FreightWaves' Mike Baudendistel discusses last week's retail earnings and interviews Guillermo Garcia, Co-Founder and CEO of SmartHop, a fleet management software company. Follow The Stockout Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 1: Current management of higher-risk myelodysplastic syndromes (MDS) — Guillermo Garcia-Manero, MD CME information and select publications  

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don't miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don't miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don't miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don't miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don't miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don't miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Go online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It's a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? Find out by viewing this activity, based on a recent live symposium, where leading experts examine the connection between the latest evidence and the real-world practice of personalized, risk-adapted MDS management. During this program, you'll see how foundational lectures link directly to "Case Forum" discussions that explore baseline prognostic assessment and the integration of novel therapeutics into the management of lower- and higher-risk disease. Don't miss this engaging and case-centered activity! Upon completion of this activity, participants should be better able to: Describe the patient- and disease-related features, including age and molecular/cytogenetic features along with risk assessment, that influence prognosis and guide treatment decisions for MDS; Summarize the updated clinical efficacy and safety evidence on currently approved and emerging treatments for newly diagnosed or relapsed/refractory MDS; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Develop strategies to address the unique spectrum of adverse events associated with novel and emerging therapies for MDS.

Go online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It's a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? Find out by viewing this activity, based on a recent live symposium, where leading experts examine the connection between the latest evidence and the real-world practice of personalized, risk-adapted MDS management. During this program, you'll see how foundational lectures link directly to "Case Forum" discussions that explore baseline prognostic assessment and the integration of novel therapeutics into the management of lower- and higher-risk disease. Don't miss this engaging and case-centered activity! Upon completion of this activity, participants should be better able to: Describe the patient- and disease-related features, including age and molecular/cytogenetic features along with risk assessment, that influence prognosis and guide treatment decisions for MDS; Summarize the updated clinical efficacy and safety evidence on currently approved and emerging treatments for newly diagnosed or relapsed/refractory MDS; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Develop strategies to address the unique spectrum of adverse events associated with novel and emerging therapies for MDS.

Go online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It's a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? Find out by viewing this activity, based on a recent live symposium, where leading experts examine the connection between the latest evidence and the real-world practice of personalized, risk-adapted MDS management. During this program, you'll see how foundational lectures link directly to "Case Forum" discussions that explore baseline prognostic assessment and the integration of novel therapeutics into the management of lower- and higher-risk disease. Don't miss this engaging and case-centered activity! Upon completion of this activity, participants should be better able to: Describe the patient- and disease-related features, including age and molecular/cytogenetic features along with risk assessment, that influence prognosis and guide treatment decisions for MDS; Summarize the updated clinical efficacy and safety evidence on currently approved and emerging treatments for newly diagnosed or relapsed/refractory MDS; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Develop strategies to address the unique spectrum of adverse events associated with novel and emerging therapies for MDS.

Go online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It's a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? Find out by viewing this activity, based on a recent live symposium, where leading experts examine the connection between the latest evidence and the real-world practice of personalized, risk-adapted MDS management. During this program, you'll see how foundational lectures link directly to "Case Forum" discussions that explore baseline prognostic assessment and the integration of novel therapeutics into the management of lower- and higher-risk disease. Don't miss this engaging and case-centered activity! Upon completion of this activity, participants should be better able to: Describe the patient- and disease-related features, including age and molecular/cytogenetic features along with risk assessment, that influence prognosis and guide treatment decisions for MDS; Summarize the updated clinical efficacy and safety evidence on currently approved and emerging treatments for newly diagnosed or relapsed/refractory MDS; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Develop strategies to address the unique spectrum of adverse events associated with novel and emerging therapies for MDS.

Go online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It's a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? Find out by viewing this activity, based on a recent live symposium, where leading experts examine the connection between the latest evidence and the real-world practice of personalized, risk-adapted MDS management. During this program, you'll see how foundational lectures link directly to "Case Forum" discussions that explore baseline prognostic assessment and the integration of novel therapeutics into the management of lower- and higher-risk disease. Don't miss this engaging and case-centered activity! Upon completion of this activity, participants should be better able to: Describe the patient- and disease-related features, including age and molecular/cytogenetic features along with risk assessment, that influence prognosis and guide treatment decisions for MDS; Summarize the updated clinical efficacy and safety evidence on currently approved and emerging treatments for newly diagnosed or relapsed/refractory MDS; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Develop strategies to address the unique spectrum of adverse events associated with novel and emerging therapies for MDS.

Go online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It's a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? Find out by viewing this activity, based on a recent live symposium, where leading experts examine the connection between the latest evidence and the real-world practice of personalized, risk-adapted MDS management. During this program, you'll see how foundational lectures link directly to "Case Forum" discussions that explore baseline prognostic assessment and the integration of novel therapeutics into the management of lower- and higher-risk disease. Don't miss this engaging and case-centered activity! Upon completion of this activity, participants should be better able to: Describe the patient- and disease-related features, including age and molecular/cytogenetic features along with risk assessment, that influence prognosis and guide treatment decisions for MDS; Summarize the updated clinical efficacy and safety evidence on currently approved and emerging treatments for newly diagnosed or relapsed/refractory MDS; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Develop strategies to address the unique spectrum of adverse events associated with novel and emerging therapies for MDS.

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists' case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists' case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists' case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists' case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists' case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists' case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

One Smart Hop to Owner Operator Success Today we talk with the team at Smart Hop about how their technology is helping owner operators have successful businesses. Guillermo Garcia joins Bruce on the show today to talk about why he started Smart Hop and how it helps the owner operator of today. Learn more about Smart Hop at www.smarthop.com This episode is sponsored by Drive Weather. Trip planning is critical to a successful road trip especially for professional drivers and the Drive Weather App should be in every tool kit. Drive Weather is an app that tracks the weather specific to the route you choose allowing for you to know exactly the type of weather you will run into on the trip. It can be customized and has many other features that make it a must have app for people on the road. Download the app in your app store or visit www.driveweatherapp.com This episode is sponsored by RIMS Transport who is looking for owner operators and drivers to work cross border operations out of Hamilton Ontario. You can learn more about the opportunities at www.rimstransport.com DriverVerified is an online platform that allows you to keep a profile that can be found by potential employers, sent directly to insurance professionals, or updated with documents that help you stand out from other applicants. You can learn more about DriverVerified at www.driververified.com  Set up your free profile today. About the Show LISTEN TO THE PODCAST- The show is available at www.theleadpedalpodcast.com  , ITunes, Stitcher, Spotify, Tunein, iHeartradio, SoundCloud, and other popular podcast platforms. Thanks for listening JOIN THE LEAD PEDAL PODCAST FAN CLUB www.TheLeadPedalPodcastFanClub.com LISTEN TO LEAD PEDAL RADIO at www.LeadPedalRadio.com The Lead Pedal Podcast for Truck Drivers talks all things trucking for people in the transportation industry helping them improve their business and careers. Interviews with industry professionals and truck drivers, trucking information, and other features on the industry are meant to be helpful for truck drivers and those in transportation. The Lead Pedal Podcast for Truck Drivers has main episodes released every Monday, Wednesday, and Friday with bonus material on other days. You can learn more about the host and show on our website and make sure to SUBSCRIBE to the show on your favourite podcast platform. www.theleadpedalpodcast.com What does The Lead Pedal Podcast mean? The Lead (pronounced - Led) stands for acceleration or fast-track of your career or business. It is a play on words and we certainly are not here promoting speeding in the industry. We are hoping this information will help you become a professional driver faster than if you didn't know about many of these topics. Are you enjoying the show? If so we would appreciate you leaving us a rating and review on iTunes or on your favourite podcast platform. www.theleadpedalpodcast.com Join The Lead Pedal Podcast Fan Club where are loyal fans get first chance at specials, discounts on merchandise and much more.The club is free to join and you can learn more at www.theleadpedalpodcastfanclub.com  

SmartHop cofounder Guillermo Garcia discusses why treating people fairly and supporting each other are the best business practice for smaller fleets.With more than 60 years of experience in logistics innovation, Dunavant is a family-owned business that has the knowledge to ensure global and domestic shipping practices are efficient and effective. Dunavant generates supply chain proficiency with outstanding, attentive, and expedient customer service. For more information, visit Dunavant.com.Follow FreightWaves on Apple PodcastsFollow FreightWaves on SpotifyMore FreightWaves Podcasts

SmartHop cofounder Guillermo Garcia discusses why treating people fairly and supporting each other are the best business practice for smaller fleets.Follow FreightWaves on Apple PodcastsFollow FreightWaves on SpotifyMore FreightWaves Podcasts

It's episode 61, and this week the guys chat with comedian/actor GUILLERMO GARCIA about his role on Mayans M.C., learning to do impressions at a young age, and working in the industry as an immigrant. Check it out! Find Guillermo At: Instagram: @elguillermogarcia Twitter: @ElGuilleGarcia Find Us At: Instagram: @StandbyPod Twitter: @PodStandby Twitch: twitch.tv/podstandby​​​​​​​ Network: instagram.com/comedystore... Producers: Brian Billuni, Jon Sosis, Tony Gidley Graphics: Trevor McHugh Music: Marc Robillard From The Comedy Store Podcast Network

In this episode you'll hear from Guillermo Garcia, founder and CEO of SmartHop, a technology platform that equips carriers with everything they need to run a trucking business. You'll hear how Guillermo started his logistics career in Venezuela and eventually came to the United States to start a trucking business.  He's now helping small carriers with dispatching, insurance, leasing, fuel, and payments.  Be sure to check out how SmartHop can help you via their website, and let us know what you think of this episode! 

On today's episode Dooner and The Dude are talking about the state of small trucking. With spot rates cratering, inflation starting to crush consumer spending, and diesel costing trucks a $1 a mile - it's time for a check up. SmartHop CEO and co-founder Guillermo Garcia shares the results of his company's report on ‘The State of Independent Truckers and Small Fleets.” Tom Zeis, Partner at Port X Logistics shares how drayage has now become an integral part of the supply chain and how tech is being used to fix a broken system.Andrei Unc, Vice President, Varstar Alliance talks about creating automation to work for people instead of against them.Domenic Leo, Vice President of Growth, Alvys tells us how their TMS is designed to help small carriers.Plus, diesel inventories in crisis; cocaine found at Nespresso factory; idiots in 4-wheelers and more.Visit our sponsorWatch on YouTubeSubscribe to the WTT newsletterApple PodcastsSpotifyMore FreightWaves PodcastsWith more than 60 years of experience in logistics innovation, Dunavant is a family-owned business that has the knowledge to ensure global and domestic shipping practices are efficient and effective. Dunavant generates supply chain proficiency with outstanding, attentive, and expedient customer service. For more information, visit Dunavant.com.

On today's episode Dooner and The Dude are talking about the state of small trucking. With spot rates cratering, inflation starting to crush consumer spending, and diesel costing trucks a $1 a mile - it's time for a check up. SmartHop CEO and co-founder Guillermo Garcia shares the results of his company's report on ‘The State of Independent Truckers and Small Fleets.” Tom Zeis, Partner at Port X Logistics shares how drayage has now become an integral part of the supply chain and how tech is being used to fix a broken system.Andrei Unc, Vice President, Varstar Alliance talks about creating automation to work for people instead of against them.Domenic Leo, Vice President of Growth, Alvys tells us how their TMS is designed to help small carriers.Plus, diesel inventories in crisis; cocaine found at Nespresso factory; idiots in 4-wheelers and more.Visit our sponsorWatch on YouTubeSubscribe to the WTT newsletterApple PodcastsSpotifyMore FreightWaves Podcasts

Guillermo Garcia sits down with Jack Jr and talks about dubbing porn and his beef.

I recently learned about a software called SmartHop; it's a brilliant solution for carriers who need want the resources of a big carrier but do not have the truck count. Meet the co-founder and CEO Guillermo Garcia this Friday!Electric fleets are the future. Are you ready? Discover why ChargePoint is the right partner to take your operation electric to reduce fueling costs, eliminate emissions and help you turn e-mobility into a competitive advantage. Visit chargepoint.solutions/freightwavesFollow MadGaines LIVE on Apple PodcastsFollow MadGaines LIVE on SpotifyMore FreightWaves Podcasts

On today's episode Dooner and The Dude are getting into deep water with ocean freight. What's the state of global freight and why are experts saying we won't see any relief this year? Lori Ann LaRocco, CNBC Sr. Editor of Guests and Maritime Trade Columnist for FreightWaves covers the latest on mounting congestion at ports in Asia plus the hard truth about our trade deficit. Sal Mercogliano, Ph.D., Maritime Historian at  Campbell University discusses the situation at U.S. ports, the conditions seafarers face, and what's happening with the Felicity Ace.Caitlin Murphy, Founder and CEO at Global Gateway Logistics shares her perspective on how these challenges are impacting brokers, forwarders and shippers.Guillermo Garcia, cofounder and CEO at SmartHop talks about how a blockbuster ‘21 has the company building a new HQ in Miami. Robert Patterson, senior driver trainer at Dayton Freight Lines has come up with a clever 3D printed solution for flickering trailer lights. Plus, a tribute to sailors; The People's Convoy publishes protest route; rat infestation at Family Dollar distribution center; and the Thai food that got people high. Visit our sponsorSubscribe to the WTT newsletterApple PodcastsSpotifyMore FreightWaves Podcasts Electric fleets are the future. Are you ready? Discover why ChargePoint is the right partner to take your operation electric to reduce fueling costs, eliminate emissions and help you turn e-mobility into a competitive advantage. Visit chargepoint.solutions/freightwaves

On today's episode Dooner and The Dude are getting into deep water with ocean freight. What's the state of global freight and why are experts saying we won't see any relief this year? Lori Ann LaRocco, CNBC Sr. Editor of Guests and Maritime Trade Columnist for FreightWaves covers the latest on mounting congestion at ports in Asia plus the hard truth about our trade deficit. Sal Mercogliano, Ph.D., Maritime Historian at  Campbell University discusses the situation at U.S. ports, the conditions seafarers face, and what's happening with the Felicity Ace.Caitlin Murphy, Founder and CEO at Global Gateway Logistics shares her perspective on how these challenges are impacting brokers, forwarders and shippers.Guillermo Garcia, cofounder and CEO at SmartHop talks about how a blockbuster ‘21 has the company building a new HQ in Miami. Robert Patterson, senior driver trainer at Dayton Freight Lines has come up with a clever 3D printed solution for flickering trailer lights. Plus, a tribute to sailors; The People's Convoy publishes protest route; rat infestation at Family Dollar distribution center; and the Thai food that got people high. Visit our sponsorSubscribe to the WTT newsletterApple PodcastsSpotifyMore FreightWaves Podcasts

In this episode of Startup Hustle, Andrew Morgans and Guillermo Garcia, CEO of SmartHop talk about how to find your startup's niche.   Find Startup Hustle Everywhere: https://linktr.ee/startuphustle   This episode is sponsored by Full Scale: https://fullscale.io/   Learn more about SmartHop: www.smarthop.co   Learn more about Marknology: https://www.marknology.com/ See omnystudio.com/listener for privacy information.

In today's fast-paced market, small fleet owners need to truck smarter, not harder. SmartHop enables small fleet owners to stop living load-to-load and start running their truck with a load strategy that will increase their monthly take-home pay, relieve stress, and give them more quality time to enjoy life OFF the road. Listen to Kendra Phillips, CTO of Ryder, and Guillermo Garcia, co-founder and CEO, discuss building a startup in today's environment and the way the market is moving.Follow FreightWaves on Apple PodcastsFollow FreightWaves on SpotifyMore FreightWaves PodcastsJoin the F3 Virtual Experience

In today's fast-paced market, small fleet owners need to truck smarter, not harder. SmartHop enables small fleet owners to stop living load-to-load and start running their truck with a load strategy that will increase their monthly take-home pay, relieve stress, and give them more quality time to enjoy life OFF the road. Listen to Kendra Phillips, CTO of Ryder, and Guillermo Garcia, co-founder and CEO, discuss building a startup in today's environment and the way the market is moving.Follow FreightWaves on Apple PodcastsFollow FreightWaves on SpotifyMore FreightWaves PodcastsJoin the F3 Virtual Experience

The "Because Belen" podcast is back! A new year with new episodes and new guests. But our very first guest is a familiar one. Fr. Willie joins us to discuss all the new developments of the new year. Joining him is former teacher and current Executive Director of Enrollment and Community Outreach Tommy De Quesada, '94, AKA "DQ." To stay connected with fellow Belen alumni, please sign up for BConnected: belenalumni.org.

If you missed some of the great interviews that were had during The Balearic Yacht Show, not to worry, we will be bringing you a few of them here! Meet Guillermo Garcia, Marketing Director at EVOLUTION Yacht Agents. Evolution Yacht Agents is a dedicated yacht services provider leading the yachting market in Spanish waters. Years of experience under our belt guarantee the delivery of reliable assistance to Captains, crew, as well as management, in the unique and transparent EVOway. Source: evolutionagents.com For more information on EVOLUTION YACHT AGENTS: www.evolutionagents.com https://www.linkedin.com/company/evolutionyachtagents/ https://www.facebook.com/evolutionyachtagents https://www.instagram.com/evolutionagents/ To contact Guillermo Garcia: https://www.linkedin.com/in/guillermogarcianunez/ For the Balearic Yacht Show and Balearic Marine: https://balearicmarine.org/ @evolutionagents @evolutionyachtagents @balearicyachtshow @balearicmarine @balearicyachtdestination #yachting #yacht #yachtlife #sailing #yachts #boat #boating #luxury #superyacht #luxuryyacht #boats #boatlife #sea #yachtdesign #luxurylifestyle #yachtlifestyle #yachtworld #megayacht #yachtcharter #motoryacht #sail #travel #yachtinglife #superyachts #sailboat #sailinglife #ocean #yachtinglifestyle #vlog #yachtinginternationalradio

Dr Guillermo Garcia-Manero from the MD Anderson Cancer Center discusses clinical data with new and emerging approaches for the management of myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMDS21).

Lucie Speaks with Guillermo Garcia, Marketing Director at Evolution Yacht Agents about the positivity of the show and the 2021 industry bounce back. #superyachtradio #boatshow #yachtshow #palmasuperyachtshow #yachtcharter #yachtbrokerage #yachtmanagement #yachtagent #superyachtindustry

On this episode of FreightWaves Insiders, Dooner catches up with SmartHop CEO/co-founder Guillermo Garcia to talk about living the American Dream. Guillermo's passion to elevate smaller fleets stems from his experience as a fleet owner himself. His trucking roots can be traced back to his native Venezuela, where his career began as a master production scheduler for Nestle before founding his own trucking company, ALCARIN, which amassed nearly 500 employees. After completing a master's program at Columbia University, Guillermo Garcia relocated his business to South Florida in 2012. Five years later, he, alongside fellow Venezuelan immigrants Joaquin Brillembourg and Miguel Sucre, built SmartHop, which has to date secured over $16M in funding across two rounds.SmartHop is a dispatch technology that helps smaller over-the-road truckers (over 90% of all trucking companies) compete with larger carriers through tech-powered freight dispatch and load booking, back office support, insurance, lease/rental, fuel cards and more.Subscribe to FreightWaves Insiders wherever you get your podcasts and never miss an episode. New shows drop every Thursday.Listen to more FreightWaves PodcastsSubscribe on Apple PodcastsSubscribe on Spotify

On this episode of FreightWaves Insiders, Dooner catches up with SmartHop CEO/co-founder Guillermo Garcia to talk about living the American Dream. Guillermo’s passion to elevate smaller fleets stems from his experience as a fleet owner himself. His trucking roots can be traced back to his native Venezuela, where his career began as a master production scheduler for Nestle before founding his own trucking company, ALCARIN, which amassed nearly 500 employees. After completing a master’s program at Columbia University, Guillermo Garcia relocated his business to South Florida in 2012. Five years later, he, alongside fellow Venezuelan immigrants Joaquin Brillembourg and Miguel Sucre, built SmartHop, which has to date secured over $16M in funding across two rounds.SmartHop is a dispatch technology that helps smaller over-the-road truckers (over 90% of all trucking companies) compete with larger carriers through tech-powered freight dispatch and load booking, back office support, insurance, lease/rental, fuel cards and more.Subscribe to FreightWaves Insiders wherever you get your podcasts and never miss an episode. New shows drop every Thursday.Listen to more FreightWaves PodcastsSubscribe on Apple PodcastsSubscribe on Spotify

En este episodio conversamos con Guillermo Garcia, músico, y amante de la cerveza, tanto que es parte del crew de "Pisse des Gothes" la cerveza venezolana mas premiada internacionalmente. Fue un placer compartir y aprender un poquito de este maravilloso mundo del cual los venezolanos solo hemos tenido la oportunidad de conocer poco o nada. Aquí Nadie Nos Conoce es un podcast que busca conectar con latinoamericanos, que tratan de desarrollar sus ideas aun en situaciones difíciles . . . Producción General - Alfonzo Prieto, Productora y Medio - Malu, Edición Giovanna Grippa, Musicalización y Audio - Carlos Gonzalez "Estudio Creativo". Síguenos en nuestras redes sociales: INSTAGRAM: https://www.instagram.com/aquinadienosconoce/ SPOTIFY: https://www.instagram.com/aquinadienosconoce/ Redes Sociales Guillermo Garcia https://www.instagram.com/pissedesgottes/ http://pissedesgottes.com --- Support this podcast: https://anchor.fm/aquinadienosconoce/support

Jose L Cherrez conversando con Guillermo Garcia Director general y Chief Instructor de Double Tap Tactical de Mexico.Guillermo GarciaDouble Tap Tactical Mexico:Instagram: https://www.instagram.com/doubletap.tactical/ Facebook: https://www.facebook.com/Double-TAP-Tactical-Mx-110604272959414/ Sitio web: http://www.double-tap.mx/ WhatsApp: https://wa.me/message/TLLQLUET7VNVI1 Para programar llamadas por WhatsApp o video conferencia con Jose L Cherrez:https://joselcherrez.youcanbook.me/ Donaciones para ayudar al canal de youtube:https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=YDC8Z7PMVFUDY&source=url Grupo de chat de Jose L Cherrez en Telegram:https://t.me/joselcherrezchat T-Shirts, Hoodies, stickers y otros productos de Jose L Cherrez:https://teespring.com/stores/joselcherrez Para cursos en otros piases y en línea a distancia entra a nuestro sitio web:https://gepacademy.com  Para ver videos exclusivos y privados con más temas, regístrate en mi Membresía en Youtube:https://www.youtube.com/channel/UCYAxtqzIo9gRTZPBil-zKHw/join Mis sitios Web: https://www.joselcherrez.com https://gepacademy.com  https://www.globaleliteprotection.com  Síguenos  en Instagram:https://www.instagram.com/joselcherrez/   https://www.instagram.com/gepacademy/ https://www.instagram.com/geprotection/  Síguenos en Facebook:https://www.facebook.com/joselcherrez/  https://www.facebook.com/Gepacademy/  https://www.facebook.com/geprotection/ Síguenos en Twitter:https://twitter.com/geprotection  https://twitter.com/joselcherrez Podcasts de Jose L Cherrez hablando con las personas que lo han ayudado, influenciado y colaborado en su carrera:http://joselcherrez.buzzsprout.com Ropa táctica y accesorios tácticos los pueden buscar en el siguiente enlace:https://www.amazon.com/shop/globaleliteprotectionsecurity#Doubletaptactical #JoseLCherrez #Podcast

The Transportation Intermediaries Association's August-filed petition is well-known for its request to FMCSA to essentially throw out the transparency reg in place since the early 1980s, and in other forms earlier than that. What's been discussed far less, however, is the second part of the broker group TIA's petition, that having to do with independent dispatchers.  TIA asks the agency to provide formal guidance officially limiting dispatchers to working with just a single carrier and, in cases where they work with multiple carriers, require a broker authority and bond.  For today's edition of Overdrive Radio, hear the voice one such independent dispatch service, the one-woman shop of Brittany Hamstreet's Brittany Dispatch business, headquartered in California, likewise the Brittany Dispatch customer owner-operator Brian Bent, who weighs in on just what it would mean to his business if additional regulatory requirements eventuated in Hamstreet no longer being available to negotiate loads, collaborate on scheduling and more with his business. Also, viewpoint from two larger businesses that bring technology to bear in efforts to provide value-added services to their independent owner-operator and small carrier clients -- Justin Taylor with Merge Transit and Guillermo Garcia of SmartHop. Subscribe to Overdrive's daily newsletter for ongoing news and views via http://overdriveonline.com/newsletter-signup

In each “Origins” episode, our host, Santosh, interviews industry leaders in the supply chain world, including founders, investors, and executives. Today's episode features Guillermo Garcia of SmartHop, a web-based service that matches truckers with the load board and brokers that need their services. Guillermo talked with us about the company's origins, how he got started in the supply chain business, and what truckers and businesses should focus on for success in the supply chain industry. The post Origins: Guillermo Garcia of SmartHop appeared first on The Future of Supply Chain: A Dynamo Ventures Podcast.

On this episode, Santosh chats with the Co-Founder and CEO of SmartHop, Guillermo Garcia. Guillermo and Santosh discuss how SmartHop is using artificial intelligence to enable trucking owner/operators to find and book competitive loads in their native language, and how this technology can be applied to help traditional brokerages compete with their digital counterparts.   The post #26: Using A.I. to Book Loads & Empower Trucking Entrepreneurs with Guillermo Garcia appeared first on The Future of Supply Chain: A Dynamo Ventures Podcast.

Bellator lightweight champion Michael Chandler will be our guest along with the founder of Kountermove, Aaron Ard. His companygives members the opportunity to test their MMA knowledge. Award winning journalist Rodolfo Roman along with Guillermo Garcia host the highly rated program educating the masses about the growing sport of mixed martial arts. Tweet your questions to @romandh or call in live at 714-868-0222. To sposor e-mail us at romandh@yahoo.com.